PMID- 28799414
OWN - NLM
STAT- MEDLINE
DCOM- 20180306
LR  - 20221207
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 52
IP  - 1
DP  - 2018 Jan
TI  - The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide 
      (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.
PG  - 69-77
LID - 10.1177/1060028017726348 [doi]
AB  - OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of 
      the fixed-dose combination of insulin degludec and the glucagon-like peptide-I 
      receptor agonist (GLP-1 RA), liraglutide (IDegLira) in the treatment of type 2 
      diabetes mellitus (T2DM). DATA SOURCES: A PubMed and MEDLINE search (1966 to July 
      2017) of the keywords insulin degludec, liraglutide, and type 2 diabetes mellitus 
      was conducted. References were reviewed to identify additional citations. STUDY 
      SELECTION AND DATA EXTRACTION: Articles written in English were included if they 
      evaluated the pharmacokinetics, pharmacology, clinical efficacy, or safety of 
      IDegLira in humans. DATA SYNTHESIS: IDegLira displayed pharmacokinetic and 
      pharmacodynamic properties similar to that of the individual components. IDegLira 
      has shown significant hemoglobin A1C (A1C) reductions of 1.3% to 1.9% and fasting 
      plasma glucose reductions of 45 to 65 mg/dL when used in patients with T2DM 
      previously receiving oral antihyperglycemic agents (AHAs), GLP-1 RAs, or basal 
      insulin. Weight loss also occurred when IDegLira was started in patients 
      previously receiving oral AHAs or basal insulin. Adverse effects (AEs) tended to 
      be mild and transient. The most common AEs were headache, nasopharyngitis, 
      upper-respiratory infections, and gastrointestinal disorders. Hypoglycemia risk 
      was lower with IDegLira than basal insulin alone but higher than liraglutide 
      alone. CONCLUSIONS: IDegLira may provide additional glycemic control with fewer 
      AEs for patients uncontrolled on a GLP-RA or basal insulin alone. Additional 
      studies evaluating use in patients on oral AHAs with higher A1C values and in 
      comparison to bolus insulin are needed.
FAU - Harris, Kira
AU  - Harris K
AD  - 1 Wingate University School of Pharmacy, Wingate, NC, USA.
AD  - 2 Novant Health Family Medicine Residency Program, Cornelius, NC, USA.
FAU - Nealy, Kimberly Lovin
AU  - Nealy KL
AD  - 1 Wingate University School of Pharmacy, Wingate, NC, USA.
AD  - 3 Cabarrus Family Medicine, Charlotte, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170811
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (IDegLira)
RN  - 0 (Insulin, Long-Acting)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Combinations
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*administration & dosage/therapeutic use
MH  - Insulin, Long-Acting/*administration & dosage
MH  - Liraglutide/*administration & dosage
MH  - Treatment Outcome
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - hyperglycemia
OT  - insulin degludec
OT  - liraglutide
OT  - type 2 diabetes mellitus
EDAT- 2017/08/12 06:00
MHDA- 2018/03/07 06:00
CRDT- 2017/08/12 06:00
PHST- 2017/08/12 06:00 [pubmed]
PHST- 2018/03/07 06:00 [medline]
PHST- 2017/08/12 06:00 [entrez]
AID - 10.1177/1060028017726348 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2018 Jan;52(1):69-77. doi: 10.1177/1060028017726348. Epub 2017 
      Aug 11.